Mount Sinai Tisch Cancer Center
@TischCancer
Followers
4K
Following
2K
Media
2K
Statuses
7K
Leader in cancer prevention, detection, treatment & research. @IcahnMountSinai & @MountSinaiNYC Appointments: 1-844-MD CANCER
New York, NY
Joined June 2014
Dmitriy Zamarin and Brian Brown received Collaborative Research Development Grant for “Targeting #OvarianCancer Control of the Tumor Microenvironment to Enhance Anti-Tumor Immunity" from Ovarian Cancer Research Alliance. @DmitriyZamarin @Brown_lab1 @IcahnMountSinai
@ocrahope
0
2
12
Earlier cilta-cel use is linked to stronger immune fitness in #myeloma, according to new data from the CARTITUDE program presented at #ASH25 by Samir Parekh, MD, of @TischCancer. ➡️ https://t.co/oT7YW9GQGh
0
1
1
A Multimodal AI Model May Improve Recurrence Risk Stratification in Early Breast Cancer - https://t.co/fzNG1CLeAX
#GoogleAlerts
@jsparano presents findings at #SABCS2025. @IcahnMountSinai #BreastCancer
aacr.org
New model provided better prognostic information for recurrence in HR-positive, HER2-negative breast cancer than the Oncotype DX 21-gene recurrence score, according to results presented at SABCS 2025.
0
0
2
John Mascarenhas, MD, hosts 7 hematologists from Brazil, Argentina, Mexico, and Colombia for a 3-day post #ASH25 MPN program observership. @IcahnMountSinai
0
3
13
Multimodal AI Model Prognostic for Long-Term Recurrence Following Treatment for Early Breast Cancer https://t.co/3mthI0Sgqy
@jsparano is lead investigator. @IcahnMountSinai
#SABCS2025 #BreastCancer
onclive.com
The multimodal ICM+ model was prognostic for long-term recurrence following treatment in early breast cancer.
0
0
3
@JoshuaRichterMD taking over @TargetedOnc for #ASH25. When is the right time for a CART? Groundbreaking data from Dr Samir Parekh @TischCancer shows that earlier on the course leads to better outcomes due to fitter T cells ! #mmsm
0
1
1
.@jsparano presents today at #SABCS25: GS1-09: Multimodal AI models integrating image, clinical, and molecular data for predicting early and late #BreastCancer recurrence in TAILORx General Session 1, 9:30 am–12 pm https://t.co/4BuSy1dGaV
@IcahnMountSinai
1
0
9
Study led by @Elvin_Wag shows that leukemia beginning before birth is often more aggressive, grows faster, and is harder to treat. https://t.co/YCkXiSM568 Published in @CD_AACR. @IcahnMountSinai #childhoodleukemia
news-medical.net
A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same leukemia-causing gene mutation can have dramatically different outcomes: it depends on...
0
3
4
Epkinly plus chemo elicits durable responses in relapsed/refractory diffuse large B-cell lymphoma https://t.co/zAB0ocVaMp
@JoshuaBrodyMD discusses. @IcahnMountSinai #ASH25 #lymphoma
curetoday.com
Dr. Josh Brody discussed key clinical trial findings for patients with diffuse large B-cell lymphoma.
0
3
5
Dual BCMA/CD19 CAR T-Cell Therapy AZD0120 Shows Promise for Multiple Myeloma https://t.co/TvATOP36tw With @ShambaviRichard @IcahnMountSinai
#multiplemyeloma #ASH2025
onclive.com
AZD0120 CAR T therapy shows rapid, deep responses and manageable safety in R/R myeloma, with ultra-fast manufacturing and strong early durability.
0
0
3
Could a COVID-19 vaccine improve the effectiveness of cancer immunotherapy? Sacha Gnjatic, PhD, @IcahnMountSinai, discusses in Nat Rev Clin Oncol. https://t.co/ZAUG8iAISO
0
0
1
We are pleased to present at #SABCS25
https://t.co/scsCizV6JX
@jsparano @RimapatelMD Hanna Irie, MD, PhD; Amy Tiersten, MD @IcahnMountSinai #breastcancer
mountsinai.org
The SABCS App is now available for download. iOS and Android users can access the complete program—including the Symposium abstracts—on their mobile devices. Learn more: https://t.co/AwQ3fsTj91
0
0
1
John Mascarenhas presents at #ASH2025: Bone marrow adipocytes (BMA) as novel biomarker of molecular response in pts with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A https://t.co/bQPKKjFprM Dec 8, 6-8 pm,West Halls B3-B4
0
0
4
Thrilled to share at #ASH25 that our lab’s first paper is now published in @CD_AACR! 🎉 We reveal how developmental context shapes oncofusion-driven high-risk pediatric acute myeloid leukemia. https://t.co/ZwslY4yspj
10
12
79
Douglas Tremblay, MD, presents tonight at #ASH2025: Real-world treatment patterns and clinical outcomes in patients with myelofibrosis treated with pacritinib (PAC): Results from the my-PAC study Dec 7, 6-8 pm OCCC - West Halls B3-B4 https://t.co/jzalTSDL5u
0
0
4
Adolfo Aleman, PhD, presents on Dec. 8 at #ASH2025: S100A8/A9 drives T cell exhaustion and compromises the therapeutic efficacy of bispecific antibodies in #multiplemyeloma. Samir Parekh, @ovanoekelen @IcahnMountSinai
0
1
2
#ASH25 Peripheral blood and marrow correlatives from CART4 and CART1 show that Ciltacel #CART pts w/ ^PFS had ^baseline non-CAR CD4 naive Tcells and ^ diversity with a more immunocompetent TME (^costim, MHCII, TCRA) in earlier (1-2) pLOT. Elegant work by Parekh lab @TischCancer
0
2
2
.@ShambaviRichard presents tomorrow at #ASH2025: Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory #multiplemyeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study https://t.co/b5oLp05Sh3
@IcahnMountSinai
0
0
0
We are pleased to present at #ASH2025, share our latest research findings, and learn from our colleagues. https://t.co/2YUpUfM9Rn
@IcahnMountSinai
mountsinai.org
0
1
2